{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:40:41Z","timestamp":1792795241050,"version":"4.5.0"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,8,6]],"date-time":"2011-08-06T00:00:00Z","timestamp":1312588800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s10157-011-0502-5","type":"journal-article","created":{"date-parts":[[2011,8,5]],"date-time":"2011-08-05T02:03:57Z","timestamp":1312509837000},"page":"797-809","source":"Crossref","is-referenced-by-count":47,"title":["Diseases of the parathyroid gland in chronic kidney disease"],"prefix":"10.1007","volume":"15","author":[{"given":"Hirotaka","family":"Komaba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatoshi","family":"Kakuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,6]]},"reference":[{"key":"502_CR1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1677\/joe.1.06057","volume":"187","author":"JT Potts","year":"2005","unstructured":"Potts JT. Parathyroid hormone: past and present. J Endocrinol. 2005;187:311\u201325.","journal-title":"J Endocrinol"},{"key":"502_CR2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJM199507273330407","volume":"333","author":"EM Brown","year":"1995","unstructured":"Brown EM, Pollak M, Seidman CE, Seidman JG, Chou YH, Riccardi D, et al. Calcium-ion-sensing cell-surface receptors. N Engl J Med. 1995;333:234\u201340.","journal-title":"N Engl J Med"},{"key":"502_CR3","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1152\/ajprenal.00336.2004","volume":"289","author":"AS Dusso","year":"2005","unstructured":"Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289:F8\u201328.","journal-title":"Am J Physiol Renal Physiol"},{"key":"502_CR4","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/ki.2008.642","volume":"75","author":"J Silver","year":"2009","unstructured":"Silver J, Naveh-Many T. Phosphate and the parathyroid. Kidney Int. 2009;75:898\u2013905.","journal-title":"Kidney Int"},{"key":"502_CR5","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1172\/JCI36479","volume":"118","author":"LD Quarles","year":"2008","unstructured":"Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008;118:3820\u20138.","journal-title":"J Clin Invest"},{"key":"502_CR6","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1074\/jbc.C500457200","volume":"281","author":"H Kurosu","year":"2006","unstructured":"Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem. 2006;281:6120\u20133.","journal-title":"J Biol Chem"},{"key":"502_CR7","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nature05315","volume":"444","author":"I Urakawa","year":"2006","unstructured":"Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770\u20134.","journal-title":"Nature"},{"key":"502_CR8","first-page":"4003","volume":"117","author":"IZ Ben-Dov","year":"2007","unstructured":"Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117:4003\u20138.","journal-title":"J Clin Invest"},{"key":"502_CR9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1677\/JOE-07-0267","volume":"195","author":"T Krajisnik","year":"2007","unstructured":"Krajisnik T, Bj\u00f6rklund P, Marsell R, Ljunggren O, Akerstr\u00f6m G, Jonsson KB, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol. 2007;195:125\u201331.","journal-title":"J Endocrinol"},{"key":"502_CR10","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1681\/ASN.V1161141","volume":"11","author":"TB Dr\u00fceke","year":"2000","unstructured":"Dr\u00fceke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol. 2000;11:1141\u201352.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 102","key":"502_CR11","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/sj.ki.5001594","volume":"70","author":"M Fukagawa","year":"2006","unstructured":"Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int. 2006;70(Suppl 102):S3\u20137.","journal-title":"Kidney Int"},{"key":"502_CR12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000327654","volume":"33","author":"M Fukagawa","year":"2011","unstructured":"Fukagawa M, Komaba H, Onishi Y, Fukuhara S, Akizawa T, Kurokawa K. Mineral metabolism management in hemodialysis patients with secondary hyperparathyroidism in Japan: baseline data from the MBD-5D. Am J Nephrol. 2011;33:427\u201337.","journal-title":"Am J Nephrol"},{"key":"502_CR13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10157-006-0432-9","volume":"10","author":"M Fukagawa","year":"2006","unstructured":"Fukagawa M, Nakanishi S, Fujii H, Hamada Y, Abe T. Regulation of parathyroid function in chronic kidney disease. Clin Exp Nephrol. 2006;10:175\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"502_CR14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0272-6386(95)90541-3","volume":"25","author":"F Llach","year":"1995","unstructured":"Llach F. Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited. Am J Kidney Dis. 1995;25:663\u201379.","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 3","key":"502_CR15","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ndt\/11.supp3.130","volume":"11","author":"E Slatopolsky","year":"1996","unstructured":"Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant. 1996;11(Suppl 3):130\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"502_CR16","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0272-6386(97)90330-9","volume":"29","author":"I Martinez","year":"1997","unstructured":"Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis. 1997;29:496\u2013502.","journal-title":"Am J Kidney Dis"},{"key":"502_CR17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ki.2009.466","volume":"77","author":"H Komaba","year":"2010","unstructured":"Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int. 2010;77:292\u20138.","journal-title":"Kidney Int"},{"key":"502_CR18","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.2009121293","volume":"21","author":"M Wolf","year":"2010","unstructured":"Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010;21:1427\u201335.","journal-title":"J Am Soc Nephrol"},{"key":"502_CR19","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.2215\/CJN.02640310","volume":"5","author":"OM Guti\u00e9rrez","year":"2010","unstructured":"Guti\u00e9rrez OM. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the \u201ctrade-off\u201d hypothesis. Clin J Am Soc Nephrol. 2010;5:1710\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"key":"502_CR20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","volume":"19","author":"T Shimada","year":"2004","unstructured":"Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429\u201335.","journal-title":"J Bone Miner Res"},{"key":"502_CR21","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA. 2001;98:6500\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"502_CR22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1053\/j.ajkd.2004.04.029","volume":"44","author":"T Shigematsu","year":"2004","unstructured":"Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis. 2004;44:250\u20136.","journal-title":"Am J Kidney Dis"},{"key":"502_CR23","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1681\/ASN.2005010052","volume":"16","author":"O Gutierrez","year":"2005","unstructured":"Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205\u201315.","journal-title":"J Am Soc Nephrol"},{"key":"502_CR24","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1523-1755.2005.00184.x","volume":"67","author":"S Nakanishi","year":"2005","unstructured":"Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int. 2005;67:1171\u20138.","journal-title":"Kidney Int"},{"key":"502_CR25","doi-asserted-by":"crossref","first-page":"c94","DOI":"10.1159\/000086347","volume":"101","author":"H Nishi","year":"2005","unstructured":"Nishi H, Nii-Kono T, Nakanishi S, Yamazaki Y, Yamashita T, Fukumoto S, et al. Intravenous calcitriol therapy increases serum concentration of fibroblast growth factor 23 in dialysis patients with secondary hyperparathyroidism. Nephron Clin Pract. 2005;101:c94\u20139.","journal-title":"Nephron Clin Pract"},{"key":"502_CR26","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS, Guti\u00e9rrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370\u20138.","journal-title":"Kidney Int"},{"key":"502_CR27","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/ki.2010.313","volume":"78","author":"H Hasegawa","year":"2010","unstructured":"Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010;78:975\u201380.","journal-title":"Kidney Int"},{"key":"502_CR28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/MNH.0b013e3281c55ede","volume":"16","author":"T Naveh-Many","year":"2007","unstructured":"Naveh-Many T, Nechama M. Regulation of parathyroid hormone mRNA stability by calcium, phosphate and uremia. Curr Opin Nephrol Hypertens. 2007;16:305\u201310.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"502_CR29","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1172\/JCI39522","volume":"119","author":"M Nechama","year":"2009","unstructured":"Nechama M, Uchida T, Mor Yosef-Levi I, Silver J, Naveh-Many T. The peptidyl-prolyl isomerase Pin1 determines parathyroid hormone mRNA levels and stability in rat models of secondary hyperparathyroidism. J Clin Invest. 2009;119:3102\u201314.","journal-title":"J Clin Invest"},{"key":"502_CR30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2265.1997.1420959.x","volume":"46","author":"Q Wang","year":"1997","unstructured":"Wang Q, Palnitkar S, Parfitt AM. The basal rate of cell proliferation in normal human parathyroid tissue: Implications for the pathogenesis of hyperparathyroidism. Clin Endocrinol. 1997;46:343\u20139.","journal-title":"Clin Endocrinol"},{"key":"502_CR31","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/(SICI)1098-2388(199703\/04)13:2<78::AID-SSU3>3.0.CO;2-Z","volume":"13","author":"Y Tominaga","year":"1997","unstructured":"Tominaga Y, Tanaka Y, Sato K, Nagasaka T, Takagi H. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol. 1997;13:78\u201386.","journal-title":"Semin Surg Oncol"},{"key":"502_CR32","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1172\/JCI116720","volume":"92","author":"N Fukuda","year":"1993","unstructured":"Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1, 25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest. 1993;92:1436\u201343.","journal-title":"J Clin Invest"},{"key":"502_CR33","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1210\/jc.81.4.1598","volume":"81","author":"O Kifor","year":"1996","unstructured":"Kifor O, Moore FD Jr, Wang P, Goldstein M, Vassilev P, Kifor I, et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab. 1996;81:1598\u2013606.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR34","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ki.1997.41","volume":"51","author":"J Gogusev","year":"1997","unstructured":"Gogusev J, Duchambon P, Hory B, Giovannini M, Goureau Y, Sarfati E, et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int. 1997;51:328\u201336.","journal-title":"Kidney Int"},{"key":"502_CR35","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1111\/j.1523-1755.2000.00370.x","volume":"58","author":"S Yano","year":"2000","unstructured":"Yano S, Sugimoto T, Tsukamoto T, Chihara K, Kobayashi A, Kitazawa S, et al. Association of decreased calcium-sensing receptor expression with proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney Int. 2000;58:1980\u20136.","journal-title":"Kidney Int"},{"key":"502_CR36","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/j.1523-1755.2002.kid585.x","volume":"62","author":"M Tokumoto","year":"2002","unstructured":"Tokumoto M, Tsuruya K, Fukuda K, Kanai H, Kuroki S, Hirakata H. Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism. Kidney Int. 2002;62:1196\u2013207.","journal-title":"Kidney Int"},{"key":"502_CR37","doi-asserted-by":"crossref","first-page":"F1096","DOI":"10.1152\/ajprenal.00167.2005","volume":"289","author":"M Cozzolino","year":"2005","unstructured":"Cozzolino M, Lu Y, Sato T, Yang J, Suarez IG, Brancaccio D, et al. A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. Am J Physiol Renal Physiol. 2005;289:F1096\u2013102.","journal-title":"Am J Physiol Renal Physiol"},{"key":"502_CR38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1681\/ASN.2007040406","volume":"19","author":"MV Arcidiacono","year":"2008","unstructured":"Arcidiacono MV, Sato T, Alvarez-Hernandez D, Yang J, Tokumoto M, Gonzalez-Suarez I, et al. EGFR activation increases parathyroid hyperplasia and calcitriol resistance in kidney disease. J Am Soc Nephrol. 2008;19:310\u201320.","journal-title":"J Am Soc Nephrol"},{"key":"502_CR39","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/ki.2009.414","volume":"77","author":"H Komaba","year":"2010","unstructured":"Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 2010;77:232\u20138.","journal-title":"Kidney Int"},{"key":"502_CR40","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000274483","volume":"31","author":"C Kumata","year":"2010","unstructured":"Kumata C, Mizobuchi M, Ogata H, Koiwa F, Nakazawa A, Kondo F, et al. Involvement of alpha-klotho and fibroblast growth factor receptor in the development of secondary hyperparathyroidism. Am J Nephrol. 2010;31:230\u20138.","journal-title":"Am J Nephrol"},{"key":"502_CR41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/ki.2009.464","volume":"77","author":"H Galitzer","year":"2010","unstructured":"Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 2010;77:211\u20138.","journal-title":"Kidney Int"},{"key":"502_CR42","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1681\/ASN.2009040427","volume":"21","author":"R Canalejo","year":"2010","unstructured":"Canalejo R, Canalejo A, Martinez-Moreno JM, Rodriguez-Ortiz ME, Estepa JC, Mendoza FJ, et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol. 2010;21:1125\u201335.","journal-title":"J Am Soc Nephrol"},{"key":"502_CR43","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/ki.1993.64","volume":"43","author":"DJ Sherrard","year":"1993","unstructured":"Sherrard DJ, Hercz G, Pei Y, Maloney NA, Greenwood C, Manuel A, et al. The spectrum of bone disease in endstage renal failure\u2014an evolving disorder. Kidney Int. 1993;43:436\u201342.","journal-title":"Kidney Int"},{"key":"502_CR44","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ki.1993.323","volume":"44","author":"G Hercz","year":"1993","unstructured":"Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, et al. Aplastic osteodystrophy without aluminium: the role of \u2018suppressed\u2019 parathyroid function. Kidney Int. 1993;44:860\u20136.","journal-title":"Kidney Int"},{"key":"502_CR45","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/0272-6386(95)90453-0","volume":"26","author":"M Wang","year":"1995","unstructured":"Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminium toxicity. Am J Kidney Dis. 1995;26:836\u201344.","journal-title":"Am J Kidney Dis"},{"key":"502_CR46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/ki.2009.374","volume":"77","author":"JC Souberbielle","year":"2010","unstructured":"Souberbielle JC, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int. 2010;77:93\u2013100.","journal-title":"Kidney Int"},{"key":"502_CR47","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bone.2008.12.016","volume":"44","author":"H Komaba","year":"2009","unstructured":"Komaba H, Goto S, Fukagawa M. Critical issues of PTH assays in CKD. Bone. 2009;44:666\u201370.","journal-title":"Bone"},{"key":"502_CR48","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1210\/jcem-28-7-1037","volume":"28","author":"SA Berson","year":"1968","unstructured":"Berson SA, Yalow RS. Immunochemical heterogeneity of parathyroid hormone in plasma. Clin Endocrinol Metab. 1968;28:1037\u201347.","journal-title":"Clin Endocrinol Metab"},{"key":"502_CR49","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/clinchem\/33.8.1364","volume":"33","author":"SR Nussbaum","year":"1987","unstructured":"Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem. 1987;33:1364\u20137.","journal-title":"Clin Chem"},{"key":"502_CR50","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1210\/jc.81.11.3923","volume":"81","author":"JH Brossard","year":"1996","unstructured":"Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barre M, D\u2019Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab. 1996;81:3923\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR51","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/en.143.1.171","volume":"143","author":"P Divieti","year":"2002","unstructured":"Divieti P, John MR, J\u00fcppner H, Bringhurst FR. Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH\/PTHrP receptor. Endocrinology. 2002;143:171\u20136.","journal-title":"Endocrinology"},{"issue":"Suppl 102","key":"502_CR52","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1038\/sj.ki.5001599","volume":"70","author":"P D\u2019Amour","year":"2006","unstructured":"D\u2019Amour P. Circulating PTH molecular forms: what we know and what we don\u2019t. Kidney Int. 2006;70(Suppl 102):S29\u201333.","journal-title":"Kidney Int"},{"key":"502_CR53","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1210\/jc.84.11.4287","volume":"84","author":"MR John","year":"1999","unstructured":"John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, J\u00fcppner H. A novel immunoradiometric assay detects full-length human PTH but not aminoterminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab. 1999;84:4287\u201390.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR54","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.ki.5001606","volume":"70","author":"JC Souberbielle","year":"2006","unstructured":"Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, et al. Intermethod variability in PTH measurement: implication for the care of CKD patients. Kidney Int. 2006;70:345\u201350.","journal-title":"Kidney Int"},{"key":"502_CR55","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1053\/j.ajkd.2008.01.017","volume":"51","author":"D Joly","year":"2008","unstructured":"Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis. 2008;51:987\u201395.","journal-title":"Am J Kidney Dis"},{"key":"502_CR56","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1046\/j.1523-1755.2001.00949.x","volume":"60","author":"MC Monier-Faugere","year":"2001","unstructured":"Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, et al. Improved assessment of bone turnover by the PTH-(1-84) large C-PTH fragments ratio in ESRD patients. Kidney Int. 2001;60:1460\u20138.","journal-title":"Kidney Int"},{"key":"502_CR57","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1053\/ajkd.2002.34519","volume":"40","author":"G Coen","year":"2002","unstructured":"Coen G, Bonucci E, Ballanti P, Balducci A, Calabria S, Nicolai GA, et al. PTH 1-84 and PTH \u201c7-84\u201d in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis. 2002;40:348\u201354.","journal-title":"Am J Kidney Dis"},{"key":"502_CR58","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1523-1755.2005.00513.x","volume":"68","author":"G Lehmann","year":"2005","unstructured":"Lehmann G, Stein G, H\u00fcller M, Schemer R, Ramakrishnan K, Goodman WG. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int. 2005;68:1206\u201314.","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"502_CR59","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1744-9987.2011.00928.x","volume":"15","author":"H Tanaka","year":"2011","unstructured":"Tanaka H, Komaba H, Koizumi M, Kakuta T, Fukagawa M. Novel electrochemiluminescence immunoassay exclusively for full-length parathyroid hormone during treatment with cinacalcet for secondary hyperparathyroidism. Ther Apher Dial. 2011;15(Suppl 1):56\u201361.","journal-title":"Ther Apher Dial"},{"issue":"Suppl 1","key":"502_CR60","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1053\/ajkd.2001.27436","volume":"38","author":"S Nakanishi","year":"2001","unstructured":"Nakanishi S, Kazama JJ, Shigematsu T, Iwasaki Y, Cantor TL, Kurosawa T, et al. Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. Am J Kidney Dis. 2001;38(Suppl 1):S172\u20134.","journal-title":"Am J Kidney Dis"},{"key":"502_CR61","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1373\/clinchem.2003.026831","volume":"50","author":"M Inaba","year":"2004","unstructured":"Inaba M, Nakatsuka K, Imanishi Y, Watanabe M, Mamiya Y, Ishimura E, et al. Technical and clinical characterization of the Bio-PTH(1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clin Chem. 2004;50:385\u201390.","journal-title":"Clin Chem"},{"key":"502_CR62","doi-asserted-by":"crossref","first-page":"525","DOI":"10.2215\/CJN.01391005","volume":"1","author":"T Arakawa","year":"2006","unstructured":"Arakawa T, D\u2019Amour P, Rousseau L, Brossard JH, Sakai M, Kasumoto H, et al. Overproduction and secretion of a novel amino-terminal form of parathyroid hormone from a severe type of parathyroid hyperplasia in uremia. Clin J Am Soc Nephrol. 2006;1:525\u201331.","journal-title":"Clin J Am Soc Nephrol"},{"key":"502_CR63","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5414\/CNP64069","volume":"64","author":"M Tanaka","year":"2005","unstructured":"Tanaka M, Itoh K, Matsushita K, Matsushita K, Fujii H, Fukagawa M. Normalization of reversed bio-intact-PTH(1-84)\/intact-PTH ratio after parathyroidectomy in a patient with severe secondary hyperparathyroidism. Clin Nephrol. 2005;64:69\u201372.","journal-title":"Clin Nephrol"},{"key":"502_CR64","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/ndt\/gfm891","volume":"23","author":"H Komaba","year":"2008","unstructured":"Komaba H, Takeda Y, Abe T, Komaba K, Otsuki N, Nibu K, et al. Spontaneous remission of severe hyperparathyroidism with normalization of the reversed whole PTH\/intact PTH ratio in a haemodialysis patient. Nephrol Dial Transplant. 2008;23:1760\u20132.","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 3","key":"502_CR65","doi-asserted-by":"crossref","first-page":"iii54","DOI":"10.1093\/ndtplus\/sfn088","volume":"1","author":"H Komaba","year":"2008","unstructured":"Komaba H, Takeda Y, Shin J, Tanaka R, Kakuta R, Tominaga Y, et al. Reversed whole PTH\/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review. NDT Plus. 2008;1(Suppl 3):iii54\u20138.","journal-title":"NDT Plus"},{"key":"502_CR66","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/ndt\/gfp578","volume":"25","author":"H Komaba","year":"2010","unstructured":"Komaba H, Shin J, Fukagawa M. Restoration of reversed whole PTH\/intact PTH ratio and reduction in parathyroid gland vascularity during cinacalcet therapy for severe hyperparathyroidism in a uraemic patient. Nephrol Dial Transplant. 2010;25:638\u201341.","journal-title":"Nephrol Dial Transplant"},{"key":"502_CR67","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1373\/clinchem.2003.021592","volume":"49","author":"P D\u2019Amour","year":"2003","unstructured":"D\u2019Amour P, Brossard JH, Rousseau L, Roy L, Gao P, Cantor T. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH(1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem. 2003;49:2037\u201344.","journal-title":"Clin Chem"},{"key":"502_CR68","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/j.1365-2265.2005.02286.x","volume":"62","author":"A R\u00e4kel","year":"2005","unstructured":"R\u00e4kel A, Brossard JH, Patenaude JV, Albert C, Nassif E, Cantor T, et al. Overproduction of an amino-terminal form of PTH distinct from human PTH(1-84) in a case of severe primary hyperparathyroidism: influence of medical treatment and surgery. Clin Endocrinol. 2005;62:721\u20137.","journal-title":"Clin Endocrinol"},{"key":"502_CR69","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1373\/clinchem.2007.085506","volume":"53","author":"MR Rubin","year":"2007","unstructured":"Rubin MR, Silverberg SJ, D\u2019Amour P, Brossard JH, Rousseau L, Sliney J Jr, et al. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1-84) is overproduced in parathyroid carcinoma. Clin Chem. 2007;53:1470\u20136.","journal-title":"Clin Chem"},{"key":"502_CR70","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1210\/jc.2009-2791","volume":"95","author":"E Cavalier","year":"2010","unstructured":"Cavalier E, Daly AF, Betea D, Pruteanu-Apetrii PN, Delanaye P, Stubbs P, et al. The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab. 2010;95:3745\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 3","key":"502_CR71","doi-asserted-by":"crossref","first-page":"iii59","DOI":"10.1093\/ndtplus\/sfn089","volume":"1","author":"M Tanaka","year":"2008","unstructured":"Tanaka M, Komaba H, Itoh K, Matsushita K, Matshushita K, Hamada Y, et al. The whole-PTH\/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism. NDT Plus. 2008;1(Suppl 3):iii59\u201362.","journal-title":"NDT Plus"},{"key":"502_CR72","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJM199507203330307","volume":"333","author":"KA Hruska","year":"1995","unstructured":"Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med. 1995;333:166\u201374.","journal-title":"N Engl J Med"},{"key":"502_CR73","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5001754","volume":"70","author":"M Jadoul","year":"2006","unstructured":"Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2006;70:1358\u201366.","journal-title":"Kidney Int"},{"key":"502_CR74","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208\u201318.","journal-title":"J Am Soc Nephrol"},{"key":"502_CR75","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jama.2011.308","volume":"305","author":"SC Palmer","year":"2011","unstructured":"Palmer SC, Hayen A, Macaskill P, Pellegrini F, Craig JC, Elder GJ, et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA. 2011;305:1119\u201327.","journal-title":"JAMA"},{"key":"502_CR76","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Dr\u00fceke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945\u201353.","journal-title":"Kidney Int"},{"issue":"Suppl 113","key":"502_CR77","first-page":"S1","volume":"76","author":"Kidney Disease","year":"2009","unstructured":"Disease Kidney, Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76(Suppl 113):S1\u2013130.","journal-title":"Kidney Int"},{"key":"502_CR78","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2215\/CJN.02830608","volume":"4","author":"SM Sprague","year":"2009","unstructured":"Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009;4:178\u201385.","journal-title":"Clin J Am Soc Nephrol"},{"key":"502_CR79","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","volume":"5","author":"RB Oliveira","year":"2010","unstructured":"Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD\u2013MBD therapy? Clin J Am Soc Nephrol. 2010;5:286\u201391.","journal-title":"Clin J Am Soc Nephrol"},{"key":"502_CR80","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMra0912522","volume":"362","author":"M Tonelli","year":"2010","unstructured":"Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010;362:1312\u201324.","journal-title":"N Engl J Med"},{"key":"502_CR81","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/ndt\/gfq124","volume":"25","author":"N Carrillo-L\u00f3pez","year":"2010","unstructured":"Carrillo-L\u00f3pez N, Fern\u00e1ndez-Mart\u00edn JL, Alvarez-Hern\u00e1ndez D, Gonz\u00e1lez-Su\u00e1rez I, Castro-Santos P, Rom\u00e1n-Garc\u00eda P, et al. Lanthanum activates calcium-sensing receptor and enhances sensitivity to calcium. Nephrol Dial Transplant. 2010;25:2930\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"502_CR82","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1172\/JCI111639","volume":"74","author":"E Slatopolsky","year":"1984","unstructured":"Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1, 25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest. 1984;74:2136\u201343.","journal-title":"J Clin Invest"},{"issue":"Suppl 5","key":"502_CR83","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1053\/ajkd.2001.28114","volume":"38","author":"F Llach","year":"2001","unstructured":"Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis. 2001;38(Suppl 5):S45\u201350.","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 10","key":"502_CR84","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ndt\/17.suppl_10.28","volume":"17","author":"T Akizawa","year":"2002","unstructured":"Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Ohashi Y, Ogata E, et al. Long-term effect of 1, 25-dihydroxy-22-oxavitamin D3 on secondary hyperparathyroidism in haemodialysis patients. One-year administration study. Nephrol Dial Transplant. 2002;17(Suppl 10):28\u201336.","journal-title":"Nephrol Dial Transplant"},{"key":"502_CR85","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000188261","volume":"68","author":"M Fukagawa","year":"1994","unstructured":"Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E, et al. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron. 1994;68:221\u20138.","journal-title":"Nephron"},{"key":"502_CR86","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1093\/ndt\/gfg451","volume":"18","author":"S Okuno","year":"2003","unstructured":"Okuno S, Ishimura E, Kitatani K, Chou H, Nagasue K, Maekawa K, et al. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2003;18:2613\u201321.","journal-title":"Nephrol Dial Transplant"},{"key":"502_CR87","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1744-9987.2006.00364.x","volume":"10","author":"Y Tominaga","year":"2006","unstructured":"Tominaga Y, Inaguma D, Matsuoka S, Tahara H, Kukita K, Kurihara S, et al. Is the volume of the parathyroid gland a predictor of maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial. 2006;10:198\u2013204.","journal-title":"Ther Apher Dial"},{"key":"502_CR88","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfg513","volume":"19","author":"T Shoji","year":"2004","unstructured":"Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant. 2004;19:179\u201384.","journal-title":"Nephrol Dial Transplant"},{"key":"502_CR89","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","volume":"16","author":"M Teng","year":"2005","unstructured":"Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hern\u00e1n MA, Camargo CA Jr, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol. 2005;16:1115\u201325.","journal-title":"J Am Soc Nephrol"},{"key":"502_CR90","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.ki.5002451","volume":"72","author":"M Wolf","year":"2007","unstructured":"Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004\u201313.","journal-title":"Kidney Int"},{"key":"502_CR91","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1093\/ndt\/gfn339","volume":"23","author":"G Jean","year":"2008","unstructured":"Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, et al. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant. 2008;23:3670\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"502_CR92","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/sj.ki.5000394","volume":"70","author":"CS Ritter","year":"2006","unstructured":"Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ. 25-hydroxyvitamin D3 suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int. 2006;70:654\u20139.","journal-title":"Kidney Int"},{"key":"502_CR93","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2215\/CJN.02140309","volume":"4","author":"K Kalantar-Zadeh","year":"2009","unstructured":"Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1529\u201339.","journal-title":"Clin J Am Soc Nephrol"},{"key":"502_CR94","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516\u201325.","journal-title":"N Engl J Med"},{"key":"502_CR95","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ndt\/gfm534","volume":"23","author":"M Fukagawa","year":"2008","unstructured":"Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant. 2008;23:328\u201335.","journal-title":"Nephrol Dial Transplant"},{"key":"502_CR96","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.03591006","volume":"3","author":"P Messa","year":"2008","unstructured":"Messa P, Mac\u00e1rio F, Yaqoob M, Bouman K, Braun J, von Albertini B, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar\/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2008;3:36\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"key":"502_CR97","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2215\/CJN.01040308","volume":"3","author":"S Fishbane","year":"2008","unstructured":"Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol. 2008;3:1718\u201325.","journal-title":"Clin J Am Soc Nephrol"},{"key":"502_CR98","doi-asserted-by":"crossref","first-page":"898","DOI":"10.2215\/CJN.04381206","volume":"2","author":"GM Chertow","year":"2007","unstructured":"Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol. 2007;2:898\u2013905.","journal-title":"Clin J Am Soc Nephrol"},{"key":"502_CR99","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.2215\/CJN.02110310","volume":"5","author":"H Komaba","year":"2010","unstructured":"Komaba H, Nakanishi S, Fujimori A, Tanaka M, Shin J, Shibuya K, et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2010;5:2305\u201314.","journal-title":"Clin J Am Soc Nephrol"},{"key":"502_CR100","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1681\/ASN.V115903","volume":"11","author":"J Chin","year":"2000","unstructured":"Chin J, Miller SC, Wada M, Nagano N, Nemeth EF, Fox J. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol. 2000;11:903\u201311.","journal-title":"J Am Soc Nephrol"},{"key":"502_CR101","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1097\/01.ASN.0000141016.20133.33","volume":"15","author":"M Mizobuchi","year":"2004","unstructured":"Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K, et al. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol. 2004;15:2579\u201387.","journal-title":"J Am Soc Nephrol"},{"key":"502_CR102","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/(SICI)1098-2388(199703\/04)13:2<87::AID-SSU4>3.0.CO;2-Y","volume":"13","author":"Y Tominaga","year":"1997","unstructured":"Tominaga Y, Numano M, Tanaka Y, Uchida K, Takagi H. Surgical treatment of renal hyperparathyroidism. Semin Surg Oncol. 1997;13:87\u201396.","journal-title":"Semin Surg Oncol"},{"key":"502_CR103","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1111\/j.1523-1755.2004.00972.x","volume":"66","author":"B Kestenbaum","year":"2004","unstructured":"Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int. 2004;66:2010\u20136.","journal-title":"Kidney Int"},{"key":"502_CR104","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00268-006-0693-1","volume":"31","author":"A Trombetti","year":"2007","unstructured":"Trombetti A, Stoermann C, Robert JH, Herrmann FR, Pennisi P, Martin PY, et al. Survival after parathyroidectomy in patients with end-stage renal disease and severe hyperparathyroidism. World J Surg. 2007;31:1014\u201321.","journal-title":"World J Surg"},{"key":"502_CR105","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.surg.2007.06.015","volume":"142","author":"V Costa-Hong","year":"2007","unstructured":"Costa-Hong V, Jorgetti V, Gowdak LH, Moyses RM, Krieger EM, De Lima JJ. Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery. 2007;142:699\u2013703.","journal-title":"Surgery"},{"key":"502_CR106","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1681\/ASN.2007010022","volume":"18","author":"KD Rudser","year":"2007","unstructured":"Rudser KD, de Boer IH, Dooley A, Young B, Kestenbaum B. Fracture risk after parathyroidectomy among chronic hemodialysis patients. J Am Soc Nephrol. 2007;18:2401\u20137.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 3","key":"502_CR107","first-page":"iii65","volume":"18","author":"Y Tominaga","year":"2003","unstructured":"Tominaga Y, Katayama A, Sato T, Matsuoka S, Goto N, Haba T, et al. Re-operation is frequently required when parathyroid glands remain after initial parathyroidectomy for advanced secondary hyperparathyroidism in uraemic patients. Nephrol Dial Transplant. 2003;18(Suppl 3):iii65\u201370.","journal-title":"Nephrol Dial Transplant"},{"key":"502_CR108","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/ki.1994.373","volume":"46","author":"M Kitaoka","year":"1994","unstructured":"Kitaoka M, Fukagawa M, Ogata E, Kurokawa K. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int. 1994;46:1110\u20137.","journal-title":"Kidney Int"},{"key":"502_CR109","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1046\/j.1523-1755.2003.00154.x","volume":"64","author":"K Shiizaki","year":"2003","unstructured":"Shiizaki K, Hatamura I, Negi S, Narukawa N, Mizobuchi M, Sakaguchi T, et al. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int. 2003;64:992\u20131003.","journal-title":"Kidney Int"},{"key":"502_CR110","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/ndt\/gfl620","volume":"22","author":"F Koiwa","year":"2007","unstructured":"Koiwa F, Kakuta T, Tanaka R, Yumita S. Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2007;22:522\u20138.","journal-title":"Nephrol Dial Transplant"},{"key":"502_CR111","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1359\/JBMR.050910","volume":"21","author":"RA Wermers","year":"2006","unstructured":"Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993\u20132001: an update on the changing epidemiology of the disease. J Bone Miner Res. 2006;21:171\u20137.","journal-title":"J Bone Miner Res"},{"key":"502_CR112","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.otohns.2004.10.005","volume":"132","author":"JM Ruda","year":"2005","unstructured":"Ruda JM, Hollenbeak CS, Stack BC Jr, et al. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg. 2005;132:359\u201372.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"502_CR113","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJM199011083231907","volume":"323","author":"SR Nussbaum","year":"1990","unstructured":"Nussbaum SR, Gaz RD, Arnold A. Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med. 1990;323:1324\u20138.","journal-title":"N Engl J Med"},{"key":"502_CR114","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1210\/jc.2005-2095","volume":"91","author":"JN VanHouten","year":"2006","unstructured":"VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, et al. Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene. J Clin Endocrinol Metab. 2006;91:580\u20133.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR115","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00005792-197403000-00002","volume":"53","author":"LE Mallette","year":"1974","unstructured":"Mallette LE, Bilezikian JP, Heath DA, Aurbach GD. Primary hyperparathyroidism: clinical and biochemical features. Medicine (Baltimore). 1974;53:127\u201346.","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 2","key":"502_CR116","first-page":"N57","volume":"17","author":"JP Bilezikian","year":"2002","unstructured":"Bilezikian JP, Potts JT Jr. Asymptomatic primary hyperparathyroidism: new issues and new questions\u2014bridging the past with the future. J Bone Miner Res. 2002;17(Suppl 2):N57\u201367.","journal-title":"J Bone Miner Res"},{"key":"502_CR117","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMcp032200","volume":"350","author":"JP Bilezikian","year":"2004","unstructured":"Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med. 2004;350:1746\u201351.","journal-title":"N Engl J Med"},{"key":"502_CR118","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1210\/jc.2008-1763","volume":"94","author":"JP Bilezikian","year":"2009","unstructured":"Bilezikian JP, Khan AA, Potts JT Jr. Summary statement: guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009;94:335\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR119","first-page":"315","volume":"42","author":"D Mizumoto","year":"1994","unstructured":"Mizumoto D, Watanabe Y, Fukuzawa Y, Aoi N, Yamazaki C. Clinical profile and outcome of primary hyperparathyroidism accompanied by chronic renal failure. Clin Nephrol. 1994;42:315\u201321.","journal-title":"Clin Nephrol"},{"key":"502_CR120","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00774-009-0053-y","volume":"27","author":"R Jimbo-Saito","year":"2009","unstructured":"Jimbo-Saito R, Ubara Y, Kadoguchi H, Suwabe T, Nakanishi S, Higa Y, et al. A case of primary hyperparathyroidism with severe bone and renal changes. J Bone Miner Metab. 2009;27:727\u201332.","journal-title":"J Bone Miner Metab"},{"key":"502_CR121","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","volume":"71","author":"A Levin","year":"2007","unstructured":"Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31\u20138.","journal-title":"Kidney Int"},{"issue":"4 Suppl 1","key":"502_CR122","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1053\/ajkd.2001.27432","volume":"38","author":"Y Tominaga","year":"2001","unstructured":"Tominaga Y, Uchida K, Haba T, Katayama A, Sato T, Hibi Y, et al. More than 1,000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. Am J Kidney Dis. 2001;38(4 Suppl 1):S168\u201371.","journal-title":"Am J Kidney Dis"},{"key":"502_CR123","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMc0802570","volume":"359","author":"AY Au","year":"2008","unstructured":"Au AY, McDonald K, Gill A, Sywak M, Diamond T, Conigrave AD, et al. PTH mutation with primary hyperparathyroidism and undetectable intact PTH. N Engl J Med. 2008;359:1184\u20136.","journal-title":"N Engl J Med"},{"key":"502_CR124","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJM199910213411701","volume":"341","author":"SJ Silverberg","year":"1999","unstructured":"Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341:1249\u201355.","journal-title":"N Engl J Med"},{"key":"502_CR125","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1210\/jc.83.11.3845","volume":"83","author":"M Abdelhadi","year":"1998","unstructured":"Abdelhadi M, Nordenstr\u00f6m J. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. J Clin Endocrinol Metab. 1998;83:3845\u201351.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7261","key":"502_CR126","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/bmj.321.7261.598","volume":"321","author":"P Vestergaard","year":"2000","unstructured":"Vestergaard P, Mollerup CL, Fr\u00f8kjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L, et al. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000;321(7261):598\u2013602.","journal-title":"BMJ"},{"issue":"7368","key":"502_CR127","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/bmj.325.7368.807","volume":"325","author":"CL Mollerup","year":"2002","unstructured":"Mollerup CL, Vestergaard P, Fr\u00f8kjaer VG, Mosekilde L, Christiansen P, Blichert-Toft M, et al. Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. BMJ. 2002;325(7368):807.","journal-title":"BMJ"},{"key":"502_CR128","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/00000658-200205000-00008","volume":"235","author":"R Udelsman","year":"2002","unstructured":"Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg. 2002;235:665\u201370.","journal-title":"Ann Surg"},{"key":"502_CR129","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/archsurg.141.4.401","volume":"141","author":"T Carling","year":"2006","unstructured":"Carling T, Donovan P, Rinder C, Udelsman R. Minimally invasive parathyroidectomy using cervical block: reasons for conversion to general anesthesia. Arch Surg. 2006;141:401\u20134.","journal-title":"Arch Surg"},{"key":"502_CR130","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00268-004-7708-6","volume":"28","author":"GL Irvin III","year":"2004","unstructured":"Irvin GL III, Solorzano CC, Carneiro DM. Quick intraoperative parathyroid hormone assay: surgical adjunct to allow limited parathyroidectomy, improve success rate, and predict outcome. World J Surg. 2004;28:1287\u201392.","journal-title":"World J Surg"},{"key":"502_CR131","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1359\/jbmr.2001.16.1.113","volume":"16","author":"M Rossini","year":"2001","unstructured":"Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res. 2001;16:113\u20139.","journal-title":"J Bone Miner Res"},{"key":"502_CR132","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/jc.2002-020890","volume":"88","author":"CC Chow","year":"2003","unstructured":"Chow CC, Chan WB, Li JK, Chan NN, Chan MH, Ko GT, et al. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:581\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR133","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1210\/jc.2003-030908","volume":"89","author":"AA Khan","year":"2004","unstructured":"Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89:3319\u201325.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR134","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2002-020667","volume":"88","author":"MR Rubin","year":"2003","unstructured":"Rubin MR, Lee KH, McMahon DJ, Silverberg SJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:1174\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR135","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1210\/jc.2002-021597","volume":"88","author":"DM Shoback","year":"2003","unstructured":"Shoback DM, Bilezikian JP, Turner SA, McCary LC, Guo MD, Peacock M. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:5644\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR136","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","volume":"90","author":"M Peacock","year":"2005","unstructured":"Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90:135\u201341.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR137","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","volume":"94","author":"C Marcocci","year":"2009","unstructured":"Marcocci C, Chanson P, Shoback D, Bilezikian J, Fernandez-Cruz L, Orgiazzi J, et al. Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94:2766\u201372.","journal-title":"J Clin Endocrinol Metab"},{"key":"502_CR138","first-page":"1049","volume":"106","author":"AM D\u2019Alessandro","year":"1989","unstructured":"D\u2019Alessandro AM, Melzer JS, Pirsch JD, Sollinger HW, Kalayoglu M, Vernon WB, et al. Tertiary hyperparathyroidism after renal transplantation: operative indications. Surgery. 1989;106:1049\u201355.","journal-title":"Surgery"},{"key":"502_CR139","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1111\/j.1600-6143.2005.00938.x","volume":"5","author":"W Gwinner","year":"2005","unstructured":"Gwinner W, Suppa S, Mengel M, Hoy L, Kreipe HH, Haller H, et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant. 2005;5:1934\u201341.","journal-title":"Am J Transplant"},{"key":"502_CR140","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1111\/j.1523-1755.2005.00303.x","volume":"67","author":"D Hern\u00e1ndez","year":"2005","unstructured":"Hern\u00e1ndez D, Rufino M, Bartolomei S, Gonz\u00e1lez-Rinne A, Lorenzo V, Cobo M, et al. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. Kidney Int. 2005;67:2015\u201320.","journal-title":"Kidney Int"},{"key":"502_CR141","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/sj.ki.5001549","volume":"70","author":"M Taniguchi","year":"2006","unstructured":"Taniguchi M, Tokumoto M, Matsuo D, Motoyama K, Sugitani A, Kuroki S, et al. Persistent hyperparathyroidism in renal allograft recipients: vitamin D receptor, calcium-sensing receptor, and apoptosis. Kidney Int. 2006;70:363\u201370.","journal-title":"Kidney Int"},{"key":"502_CR142","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1046\/j.1523-1755.2001.00755.x","volume":"59","author":"M Levi","year":"2001","unstructured":"Levi M. Post-transplant hypophosphatemia. Kidney Int. 2001;59:2377\u201387.","journal-title":"Kidney Int"},{"key":"502_CR143","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/sj.ki.5001788","volume":"70","author":"I Bhan","year":"2006","unstructured":"Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett SM, et al. Post-transplant hypophosphatemia: tertiary \u2018hyper-phosphatoninism\u2019? Kidney Int. 2006;70:1486\u201394.","journal-title":"Kidney Int"},{"key":"502_CR144","unstructured":"Kawarazaki H, Shibagaki Y, Fukumoto S, Kido R, Nakajima I, Fuchinoue S, et al. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study. Nephrol Dial Transplant (in press)."},{"key":"502_CR145","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2215\/CJN.01310308","volume":"3","author":"P Evenepoel","year":"2008","unstructured":"Evenepoel P, Meijers BK, de Jonge H, Naesens M, Bammens B, Claes K, et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol. 2008;3:1829\u201336.","journal-title":"Clin J Am Soc Nephrol"},{"key":"502_CR146","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2215\/CJN.00500705","volume":"1","author":"TR Srinivas","year":"2006","unstructured":"Srinivas TR, Schold JD, Womer KL, Kaplan B, Howard RJ, Bucci CM, et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol. 2006;1:323\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"key":"502_CR147","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/ndt\/gfl560","volume":"22","author":"AL Serra","year":"2007","unstructured":"Serra AL, Savoca R, Huber AR, Hepp U, Delsignore A, Hersberger M, et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant. 2007;22:577\u201383.","journal-title":"Nephrol Dial Transplant"},{"key":"502_CR148","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/ki.1990.144","volume":"37","author":"T Sugimoto","year":"1990","unstructured":"Sugimoto T, Ritter C, Morrissey J. Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int. 1990;37:1522\u20137.","journal-title":"Kidney Int"},{"key":"502_CR149","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/ndt\/gfm639","volume":"23","author":"R Murakami","year":"2008","unstructured":"Murakami R, Murakami S, Tsushima R, Ueda C, Mikami K, Ebina T, et al. Glycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy. Nephrol Dial Transplant. 2008;23:315\u201320.","journal-title":"Nephrol Dial Transplant"},{"key":"502_CR150","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.jrn.2009.10.006","volume":"20","author":"R Dukkipati","year":"2010","unstructured":"Dukkipati R, Kovesdy CP, Colman S, Budoff MJ, Nissenson AR, Sprague SM, et al. Association of relatively low serum parathyroid hormone with malnutrition\u2013inflammation complex and survival in maintenance hemodialysis patients. J Ren Nutr. 2010;20:243\u201354.","journal-title":"J Ren Nutr"},{"key":"502_CR151","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00041552-200007000-00007","volume":"9","author":"M Fukagawa","year":"2000","unstructured":"Fukagawa M, Akizawa T, Kurokawa K. Is aplastic osteodystrophy a disease of malnutrition? Curr Opin Nephrol Hypertens. 2000;9:363\u20137.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"502_CR152","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/ndtplus\/sfn040","volume":"1","author":"VM Brandenburg","year":"2008","unstructured":"Brandenburg VM, Floege J. Adynamic bone disease\u2014bone and beyond. NDT Plus. 2008;1:135\u201347.","journal-title":"NDT Plus"},{"issue":"Suppl 102","key":"502_CR153","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1038\/sj.ki.5001600","volume":"70","author":"Y Iwasaki","year":"2006","unstructured":"Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, et al. Insufficiency of PTH action on bone in uremia. Kidney Int. 2006;70(Suppl 102):S34\u20136.","journal-title":"Kidney Int"},{"key":"502_CR154","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0085-2538(15)47156-X","volume":"58","author":"E Slatopolsky","year":"2000","unstructured":"Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, et al. A novel mechanism for skeletal resistance in uremia. Kidney Int. 2000;58:753\u201361.","journal-title":"Kidney Int"},{"key":"502_CR155","doi-asserted-by":"crossref","unstructured":"Picton ML, Moore PR, Mawer EB, Houghton D, Freemont AJ, Hutchison AJ, Gokal R, Hoyland JA. Down-regulation of human osteoblast PTH\/PTHrP receptor mRNA in end-stage renal failure. Kidney Int. 2000;58:1440\u20139.","DOI":"10.1046\/j.1523-1755.2000.00306.x"},{"key":"502_CR156","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/ndt\/gfh876","volume":"20","author":"Y Iwasaki-Ishizuka","year":"2005","unstructured":"Iwasaki-Ishizuka Y, Yamato H, Nii-Kono T, Kurokawa K, Fukagawa M. Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol Dial Transplant. 2005;20:1904\u201311.","journal-title":"Nephrol Dial Transplant"},{"key":"502_CR157","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/ajkd.2002.31402","volume":"39","author":"JJ Kazama","year":"2002","unstructured":"Kazama JJ, Shigematsu T, Yano K, Tsuda E, Miura M, Iwasaki Y, et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis. 2002;39:525\u201332.","journal-title":"Am J Kidney Dis"},{"key":"502_CR158","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/ndt\/gfl311","volume":"21","author":"Y Iwasaki","year":"2006","unstructured":"Iwasaki Y, Yamato H, Nii-Kono T, Fujieda A, Uchida M, Hosokawa A, et al. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats. Nephrol Dial Transplant. 2006;21:2768\u201374.","journal-title":"Nephrol Dial Transplant"},{"key":"502_CR159","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/sj.ki.5002097","volume":"71","author":"T Nii-Kono","year":"2007","unstructured":"Nii-Kono T, Iwasaki Y, Uchida M, Fujieda A, Hosokawa A, Motojima M, et al. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney Int. 2007;71:738\u201343.","journal-title":"Kidney Int"},{"key":"502_CR160","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1525-139X.2010.00817.x","volume":"24","author":"SA Jamal","year":"2011","unstructured":"Jamal SA, Hodsman AB. Reducing the risk of re-fracture in the dialysis population: is it time to consider therapy with PTH analogues? Semin Dial. 2011;24:12\u20135.","journal-title":"Semin Dial"},{"key":"502_CR161","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000316708","volume":"33","author":"D Cejka","year":"2010","unstructured":"Cejka D, Kodras K, Bader T, Haas M. Treatment of hemodialysis-associated adynamic bone disease with teriparatide (PTH(1-34)): a pilot study. Kidney Blood Press Res. 2010;33:221\u20136.","journal-title":"Kidney Blood Press Res"},{"key":"502_CR162","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1172\/JCI9038","volume":"105","author":"M Gowen","year":"2000","unstructured":"Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, et al. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest. 2000;105:1595\u2013604.","journal-title":"J Clin Invest"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-011-0502-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-011-0502-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-011-0502-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T18:50:11Z","timestamp":1638211811000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-011-0502-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,6]]},"references-count":162,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1007\/s10157-011-0502-5","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,6]]}}}